Pharmacists See Challenges, Opportunities In Behind-The-Counter Class
This article was originally published in The Tan Sheet
Executive Summary
Pharmacy trade groups welcome the possibility of a behind-the-counter class of drugs, but a pharmacy professor and former FDA Nonprescription Drugs Advisory Committee chairman cautions a third class could create more demand than pharmacists are able to manage
You may also be interested in...
Von Eschenbach Promotes Behind-The-Counter Drug Class
FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew C. von Eschenbach, M.D., told OTC industry executives March 16
Barr Takes CARE To Monitor Plan B Consumer Behavior Trends
Barr plans to track whether Plan B is being used in lieu of other forms of contraception under its Convenient Access Responsible Education (CARE) postmarketing program
Pseudoephedrine Will Be Behind The Counter Across The Country By October
Retailers will have to be prepared to enforce monthly gram purchase limits on pseudoephedrine products by mid-April, once meth control provisions of the Patriot Act reauthorization bill go into effect